But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

Discover the top 19 most notable drugs approved by the FDA in 2024, including Dupixent for COPD and FluMist for self-administration. See the full list here.

Making America Healthy Again’ is a complicated, messy, and massive undertaking bound to meet resistance. Reducing nicotine in ...

Dr. Andy Whittamore, a GP and clinical lead at Asthma and Lung UK, shed light on four chronic lung conditions that tend to ...

China approves GSK's Nucala for chronic rhinosinusitis with nasal polyps, adding to its existing uses in asthma and other ...

The Dr Trust Bestest Compressor Nebulizer is a highly efficient and reliable device for home use. It features a powerful ...

Stapokibart (Kangyueda) is a humanized monoclonal antibody. It is formulated as a solution for the subcutaneous route of administration. Kangyueda is indicated for the treatment of moderate to severe ...

The medication segment was the largest in 2022, favored for its cost-effectiveness and common use as a first-line treatment. .Centriacinar Emphysema Growth: The centriacinar segment, primarily linked ...

Company has also raised $12 million in funding led by Lucius Partners NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- AerWave Medical, a leader in ultrasound-based interventional pulmonary solutions, ...

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...